Seeking Alpha

Derrick Lilly

View as an RSS Feed
View Derrick Lilly's Comments BY TICKER:
Latest  |  Highest rated
  • McEwen Mining Has A High Price But So-So Assets [View article]

    The property hasn't attracted global mining companies yet, that is the problem. Is TNR even going to monetize its back-in right? You need to buy in your share of exploration expenses. Estimates I have seen put this at around $25mm. TNR will need to sell its shares in MUX to come up with that. I don't see McEwen buying you out of the back-in right unless there is a substantial deal on the table either.
    Aug 19 12:43 PM | Likes Like |Link to Comment
  • McEwen Mining Has A High Price But So-So Assets [View article]
    I believe the hope was that Los Azules would be sold and fund CAPEX on all the other projects. Obviously that hasn't played out yet. I think you're right in suggesting Lexam will be combined with MUX. They have growing reserves up there, share a corporate office, and it could be a future catalyst. Rob has a lot of investments in other explorers/miners that may become JV targets in time. Definitely not how Goldcorp came to be, but maybe this strategy will turn out in time. Right now, low PM prices are what is really hurting El Gallo expansion.

    I've been a shareholder for many years, and I am disappointed at the performance (or lack of), but I haven't given up all hope yet. I've spent time with Rob and his team and they are competent and passionate. I know they want to do well and I believe they will make smart decisions going forward. This company has his name on it, he isn't going to let it fail. The stock has enough volatility to trade its patterns until a clearer growth plan develops.
    Aug 19 12:16 PM | Likes Like |Link to Comment
  • Kratos Defense And Security Systems: Is Everyone Wrong About This Stock? [View article]
    No mention of their $1B backlog? Bidding on contracts valued at $6B (granted they won't win all of them). They've been hurt by government delays, but their programs are proving successful. I think they may become a M&A target in time.
    Aug 15 11:10 AM | 1 Like Like |Link to Comment
  • Update: Seadrill Big Winner In Mexican Energy Deregulation [View article]
    I didn't say they would win every contract. I am saying that they already have their foot in the door to win more contracts, and they have the modern rigs that will be desirable for drilling at any depths when it's time to start drilling.

    And you asked what nuahw's comment had to do will drilling in Mexico.... Since this article is about Seadrill, he gave the example of their recent announcement for a rig in Nigeria getting a premium rate. Like I said, this is an indication that rates for new, premium rigs aren't falling like many analysts predicted, which bodes well for Seadrill earnings and others with modern fleets.
    Aug 14 02:05 PM | 2 Likes Like |Link to Comment
  • Update: Seadrill Big Winner In Mexican Energy Deregulation [View article]
    You're being naive. West Pegasus comes online in 2016 and can reach depths of 10k ft. The JV and formation of SeaMex allows for expansion throughout the region. Seadrill is already very well established with all of the majors that will likely bid on exploration/production in Mexico. The point on day rates is that they aren't collapsing for ultramodern rigs like so many predicted. There's billions of dollars worth of contracts for a company like Seadrill to win in Mexico.
    Aug 14 01:00 PM | 4 Likes Like |Link to Comment
  • Update: Seadrill Big Winner In Mexican Energy Deregulation [View article]
    Because Seadrill has the most modern UDW drill ships and already has a JV established with PEMEX.
    Aug 14 12:03 PM | 5 Likes Like |Link to Comment
  • GenCorp's Stock Could Be About To Take Off [View article]
    Another risk: They are going to lose Orbital's business.
    Jul 29 01:30 PM | 1 Like Like |Link to Comment
  • Provectus Is Still Overvalued: Accounting For Risk And Dilution Takes The Value Of This Company Below $0.20 Per Share [View article]
    I don't understand your statement here. If the drug/treatment is a joke in your view, why would a management change or insider buying change your mind?
    Jun 5 12:15 PM | Likes Like |Link to Comment
  • Marlin Gold: Gone Fishing For Gold Streams [View article]
    Marlin Gold closed the Sprott loan and a new private placement that have deemed a public equity offering unnecessary and it looks like they'll be moving forward fairly quickly now on the Golden Reign acquisition:
    May 29 03:46 PM | Likes Like |Link to Comment
  • McEwen Mining And Marlin Gold: Speculative Plays On Gold-Rich Mexico [View article]
    Here's a much-needed and welcomed update on Marlin Gold. Sprott loan and new private placement have deemed a public equity offering unnecessary and looks like they'll be moving forward fairly quickly now on the Golden Reign acquisition:
    May 29 03:39 PM | Likes Like |Link to Comment
  • Provectus Is Still Overvalued: Accounting For Risk And Dilution Takes The Value Of This Company Below $0.20 Per Share [View article]
    Yes, I have been a business/finance writer since 2008. I write content targeted mostly for the accounting/finance professionals focusing on business management, investment, m&a, career management and development, professional education and more. On my own time, I like to write about precious metals and mining when I can. When I do so, I generally try to communicate with other analysts, CFAs or other professionals familiar with the companies I have written about to make sure my facts are straight since I am not credentialed.

    Anyway, I won't disagree with you that PVCT share price is overvalued based on their financial position. PVCT reminds me of micro-cap miners. Their shares don't reflect their actual cash or earnings in most cases, but their potential: what is their land worth, how many ounces are in the ground, what value do those ounces bring if mined. In many cases, these stocks trade at valuations that seem nonsensical, then a partner steps in to bring the deposit into production or buys it out to bolster their reserves and you get a nice payday.

    That's what I see happening with PVCT if they can pull the data together correctly. That is why the stock has traded as violently as it has. It's all speculation, of course, that the drug will be brought to market here in the U.S. and in China, India and maybe Australia. Melanoma is only a portion of what they are working on. There are several cancer types that can be targeted. If PVCT proves clear benefit in one area, I see a major pharma company stepping in to buy or JV. I don't agree with the BTD application, I think they should have had all the ducks in a row before doing it, but the additions to their advisory board, St. Luke's taking on use, and the potential to do deals in India and China, etc., etc., all seem to point to some sort of future for this treatment. Could I be wrong? Absolutely. Can management totally sink the ship? Absolutely. That's why this is speculative. But if it works out, this could be worth billions to a big pharma, many of which are suffering from patent expiration.

    Everyone should be realistic about this stock though. It is totally speculative. Anyone betting their retirement on it needs to either get their head checked and quickly find new money to diversify with. If you can afford to wait, and lose what you put it, this could be an exciting ride. This is my opinion.

    I'll just add that, right now, it looks like their only hope is to nail the bridging study that they can afford to do. Without success there, dilution or dissolution definitely seems probable.
    May 29 02:07 PM | 7 Likes Like |Link to Comment
  • Provectus Is Still Overvalued: Accounting For Risk And Dilution Takes The Value Of This Company Below $0.20 Per Share [View article]
    Wow. Settle down, excapt. Your comments are only making you look unintelligent and uneducated. Your grammar is horrible, and this is really no place for blatantly emotional responses that contribute nothing to the debate.

    You're likely long PVCT and looking at huge losses in your portfolio. If you really think this treatment is going to come to market, you shouldn't be worried about what the share price is right now, or tomorrow even. What matter is if/when it comes to market or if/when a major partner steps in or a buyout occurs.

    All PVCT shareholders should be worried about the class action lawsuit that is being brought against PVCT that is going to drain much-needed cash for the bridging study and more. I'm long, but I am concerned, and I am tired of these articles that shine with bias, and I am tired of all the senseless name-calling and emotional responses.

    Get a grip people.

    And to the author, I don't care that you are short or negative, but you should really include a full-circle look at the company, not opine and grasp for the negatives alone. The management may suck, but the drug has showed promise despite you trying to downplay it. If it was nothing more than cheap food-dye that did nothing, it wouldn't have gone through Phase 2 and it wouldn't be used, researched and presented on by legitimate cancer research centers. Give credit where credit is due and be critical where needed, but for God's sake, take the extra time to be objective and thorough to some degree. Maybe consider interviewing someone professionally familiar with the drug, for instance. The penny-per-click you get from SA isn't going to benefit you, so the only other assumption most on here will have is that if you have no equity stake, then you have a greater financial interest that is undisclosed. Just saying it how it is.
    May 29 01:12 PM | 3 Likes Like |Link to Comment
  • Provectus Is Still Overvalued: Accounting For Risk And Dilution Takes The Value Of This Company Below $0.20 Per Share [View article]
    I'd encourage everyone to be objective and do their own due diligence. There's an upcoming conference call that will be of interest to all longs/shorts.

    Provectus Biopharmaceuticals Inc. to Hold Conference Call Tuesday, June 3, 2014

    The purpose of the call will be to update the market on the scientific content of the two poster presentations at American Society of Clinical Oncology annual meeting to be held at McCormick Place, Chicago, IL. In addition, the Company will lay out its plans for securing FDA approval for the use of PV-10 in the treatment of cutaneous melanoma.

    As indicated in the Company's press releases issued on May 14, 2014 and May 15, 2014, these presentations, undertaken separately by Moffitt Cancer Center and St. Luke's Cancer Center, show that IL PV-10 (a) can potentially offer cancer patients control of their cutaneous symptoms and (b) elicit a systemic anti-tumor immune response that may lead to response of uninjected lesions (the "bystander effect" that has been observed in prior clinical studies of PV-10)....

    Conference Call Tuesday June 3, 2014, at 8:30 AM EDT.... Those who wish to participate in the conference call may telephone 877-407-4019 from the U.S. International callers may telephone 201-689-8337, approximately 15 minutes before the call. A webcast will also be available at:

    A digital replay will be available by telephone approximately two hours after the completion of the call until August 3, 2014, and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, and using the Conference ID#13583791.

    The complete press release is available at on the Provectus website.
    May 29 11:26 AM | 4 Likes Like |Link to Comment
  • Provectus: Strong Sell, Ties To Paid Stock Promoters, SEC Halt Risk, Price Target $0 [View article]
    True, but according to the "guidelines" SA gives to contributors and supposedly follows regarding biotech articles, in order to be published the article should:

    "1) Core Scientific Competence: Demonstrate more than a basic familiarity with the scientific and medical knowledge necessary to judge why said drug's prospects are either bullish, bearish or neutral.

    2) Fundamental Analysis: A sound, and reasonable look at the the balance sheet, burn rate, etc. Obviously, we don’t get hung up on earnings of early-stage companies, but let readers know the financial health of the company and future prospects for the same.

    3) Potential Risks: “There is always risk in early-stage biotech” does not suffice as a risk statement. Regardless of a long or short thesis, present what hurdles must be watched for the reader to gauge the ultimate likelihood of success of your thesis.

    4) Quality Sourcing: Source material should be from reputable sources and should complement the piece, not account for the majority of it. Cutting and pasting abstracts and the like doesn’t offer unique analysis. Presenting an abstract in context of your own analysis does.

    Finally, a word on bombast. Extraordinary claims require extraordinary evidence. An article claiming a stock is going up 100% or more better be extremely well-supported. If you’re saying a drug will cure a disease, prove it. Reasoned analysis draws the right kind of crowd. Yelling from the rooftops does not."

    This "article" fails and should not have been published, IMO.
    May 23 10:52 AM | Likes Like |Link to Comment
  • Provectus: Strong Sell, Ties To Paid Stock Promoters, SEC Halt Risk, Price Target $0 [View article]
    Kretikos, done and gone sounds like a good idea for you seeing that you don't seem to have the capacity to do your research or present it fully. Again, you select one line from a very long ethics code and disclosure pertaining to all aspects of Canopy's business. Why not include the entire thing? Because it doesn't support the wrongful claim that you are trying to make that PVCT bought this report? I've already provided you with the clear cut copyright text that discloses their PVCT report was not paid for or sponsored. Whether they do other reports that are paid for is irrelevant because we are talking about "this" report, and "this" report was not bought. End of story.

    If the majority of 'retail investors' would learn to do thorough DD, God wouldn't need to save them.
    May 23 10:22 AM | 1 Like Like |Link to Comment